Compare Johnson & Johnson (JNJ) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Johnson & Johnson trades at $259.62 (market cap $618.09B), while Vanguard Intermediate Term Corporate Bond ETF trades at $78.41 (market cap $72.20B). The key difference: Johnson & Johnson is far larger — about 8.6× Vanguard Intermediate Term Corporate Bond ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vanguard Intermediate Term Corporate Bond ETF for 61 Days on average.
| JNJ | VCIT | |
|---|---|---|
Market Cap | $618.09B | $72.20B |
Volume | 6,050,983 | 7,532,796 |
Sector | Health | Fixed Income |
52-Week High | $278.43 | $84.82 |
52-Week Low | $186.00 | $77.98 |
Typical Hold Time | 129 Days | 61 Days |
Enterprise Value | $646.37B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
VCIT trades at $78.345 with minimal daily movement (+0.1%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. The ETF maintains consistent dividend distributions of $0.34 per share. Recent institutional interest includes Engineers Gate Manager LP's $1.27 million investment and HB Wealth Management's 242.9% position increase.
VCIT offers a compelling 4.8% yield with low 0.03% expense ratio, positioning it favorably against peers. However, bearish technical signals and interest rate sensitivity present near-term risks. The fund's intermediate-term corporate bond focus provides balanced risk-return profile for income-seeking investors in current economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
